# Open-label, Randomized Trial in Participants Undergoing TAVR to Determine Safety & Efficacy of Bivalirudin vs UFH

Study · id `cardio:ct-nct01651780` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01651780](<https://clinicaltrials.gov/study/NCT01651780>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01651780

Browse, organ or system: Heart  
Browse, condition area: Valve and congenital heart disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 803 participants.

## Technical summary

Registry record NCT01651780. Randomized; no masking; primary purpose treatment. Start 2012-10 (registry gives no type); primary completion 2015-06 (actual). Results posted on 2017-02-27.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 803 participants (enrolled count; ClinicalTrials.gov record NCT01651780, source copy `cardio:ctgov-nct01651780-2017-04-07`, retrieved 2026-10-26)
- Start date: 2012-10 (registry gives no type) (ClinicalTrials.gov record NCT01651780, source copy `cardio:ctgov-nct01651780-2017-04-07`, retrieved 2026-10-26)
- Primary completion: 2015-06 (actual) (ClinicalTrials.gov record NCT01651780, source copy `cardio:ctgov-nct01651780-2017-04-07`, retrieved 2026-10-26)
- Completion: 2015-06 (actual) (ClinicalTrials.gov record NCT01651780, source copy `cardio:ctgov-nct01651780-2017-04-07`, retrieved 2026-10-26)
- Results first posted: 2017-02-27 (ClinicalTrials.gov record NCT01651780, source copy `cardio:ctgov-nct01651780-2017-04-07`, retrieved 2026-10-26)
- Countries: Canada; France; Germany; Italy; Netherlands; Switzerland; United Kingdom (ClinicalTrials.gov record NCT01651780, source copy `cardio:ctgov-nct01651780-2017-04-07`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01651780-2017-04-07`, retrieved 2026-10-26)

## The registry's words

- Brief title: Open-label, Randomized Trial in Participants Undergoing TAVR to Determine Safety & Efficacy of Bivalirudin vs UFH
- Acronym: BRAVO 2/3
- Condition: Severe Aortic Stenosis
- Condition: Transcatheter Aortic Valve Replacement
- Condition: Aortic Valve Replacement
- Intervention (Drug): Bivalirudin
- Intervention (Drug): Unfractionated Heparin
- Lead sponsor: The Medicines Company
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Aortic stenosis (`cardio:aortic-stenosis`)
- Registry condition terms include this condition: Heart valve disease (`cardio:heart-valve-disease`)
- Registry intervention name matches this record: Bivalirudin (`cardio:bivalirudin`)
- Registry intervention name matches this record: Heparins and low-molecular-weight heparins (`cardio:heparins-and-low-molecular-weight-heparins`)
- Registry intervention is a member of this class by a sourced record link: Anticoagulants (`cardio:anticoagulants`)
- Registry lists this organization as the lead sponsor: The Medicines Company (`cardio:org-the-medicines-company`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Bivalirudin Versus Heparin Anticoagulation in Transcatheter Aortic Valve Replacement: The Randomized BRAVO-3 Trial (`cardio:pubmed-26477635`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Cerebral Embolism During Transcatheter Aortic Valve Replacement: The BRAVO-3 MRI Study (`cardio:pubmed-27208464`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: ec6b224078b267e01adff4a2d996db35e61102ef99f46743ef13b60e08b5e7d6
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
